title: Diffuse large B cell lymphoma without immunoglobulin light chain restriction by flow cytometry.
abstract: BACKGROUND
  The existence of immunoglobulin light chain restriction (LCR) strongly indicates B cell monoclonality. Although LCR-deficient B cell malignancies are often observed, their details are barely known.
  
  
  METHODS
  We retrospectively analyzed LCR-negative diffuse large B cell lymphoma (DLBCL) to elucidate their clinical features. Consecutive DLBCL patients (n = 119), whose histological diagnostic specimens were analyzed by flow cytometry (FCM), were divided into 2 groups: LCR-positive and LCR-negative DLBCL. Cases wherein FCM did not capture tumor cells were excluded.
  
  
  RESULTS
  There were 91 LCR-positive (76%) and 28 LCR-negative (24%) DLBCL. The 2 groups did not differ with regard to background, including the International Prognostic Index (IPI), each factor of IPI, gender, bulky mass and B-symptoms. FCM analysis showed that CD10-positive cases were less frequent in the LCR-negative DLBCL group than in the LCR-positive DLBCL group. CD5-positive cases were absent in the LCR-negative DLBCL group. Chromosomal analysis showed that the frequency of BCL2, BCL6 and MYC translocations did not differ between the groups. There was no survival difference in the groups.
  
  
  CONCLUSIONS
  LCR-negative DLBCL accounts for about one fourth of all DLBCL and their prognosis is similar to that of LCR-positive DLBCL. CD10-negative status might characterize LCR-negative DLBCL.
authors.affiliation: Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan. cavalier@ch-yamate.dlenet.com
authors.forename: Naoto
authors.initials: N
authors.lastname: Tomita
authors.forename: Kengo
authors.initials: K
authors.lastname: Takeuchi
authors.forename: Rie
authors.initials: R
authors.lastname: Hyo
authors.forename: Chizuko
authors.initials: C
authors.lastname: Hashimoto
authors.forename: Sachiya
authors.initials: S
authors.lastname: Takemura
authors.forename: Jun
authors.initials: J
authors.lastname: Taguchi
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Fujita
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Koji
authors.initials: K
authors.lastname: Ogawa
authors.forename: Shigeki
authors.initials: S
authors.lastname: Motomura
authors.forename: Yoshiaki
authors.initials: Y
authors.lastname: Ishigatsubo
mesh_terms: D000328:Adult; D000368:Aged; D000951:Antigens, Neoplasm / Q000032:analysis*; D001402:B-Lymphocytes / Q000737:chemistry / Q000473:pathology*; D018956:CD5 Antigens / Q000032:analysis; D002999:Clone Cells / Q000737:chemistry / Q000473:pathology; D004268:DNA-Binding Proteins / Q000235:genetics; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D019254:Genes, bcl-2; D016259:Genes, myc; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000032:analysis*; D007145:Immunoglobulin kappa-Chains / Q000032:analysis; D007146:Immunoglobulin lambda-Chains / Q000032:analysis; D016403:Lymphoma, Large B-Cell, Diffuse / Q000235:genetics / Q000401:mortality / Q000473:pathology*; D008297:Male; D008875:Middle Aged; D015260:Neprilysin / Q000032:analysis; D011379:Prognosis; D051560:Proto-Oncogene Proteins c-bcl-6; D012189:Retrospective Studies; D016019:Survival Analysis; D014178:Translocation, Genetic
chemical_list: D000951:Antigens, Neoplasm; C084103:BCL6 protein, human; D018956:CD5 Antigens; D004268:DNA-Binding Proteins; D007147:Immunoglobulin Light Chains; D007145:Immunoglobulin kappa-Chains; D007146:Immunoglobulin lambda-Chains; D051560:Proto-Oncogene Proteins c-bcl-6; D015260:Neprilysin